Foghorn Therapeutics Inc. SEC filings FHTX

Foghorn Therapeutics Inc. has 354 filings in SEC EDGAR's recent list, going back to Aug 28, 2020. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 1, 2026 (exit or restructuring costs, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Apr 30, 2026 —
DEF 14A Proxy statement Apr 30, 2026 Jun 24, 2026
DEFA14A Additional proxy material May 5, 2025 —
DEF 14A Proxy statement May 5, 2025 Jun 17, 2025
DEFA14A Additional proxy material May 3, 2024 —
DEF 14A Proxy statement May 3, 2024 Jun 26, 2024
DEFA14A Additional proxy material Apr 28, 2023 —
DEF 14A Proxy statement Apr 28, 2023 Jun 21, 2023
DEFA14A Additional proxy material Apr 29, 2022 —
DEF 14A Proxy statement Apr 29, 2022 Jun 21, 2022
DEF 14A Proxy statement Jun 1, 2021 Jul 8, 2021

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
FHTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1822462

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.